Evaluate Short-Term Outcomes of abciximab in ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Clinical Trials

Table 3

Baseline demographic and clinical characteristics of patients included.

	Antoniucci 2003		Brener 1998		Ernst 2004		Mehilli 2009		Montalescot 2001		Neumann 1998		Neumann 2000		Petronio 2005		Tcheng 2003		Zorman 2002
	A	C	A	C	A	C	A	C	A	C	A	C	A	C	A	C	A	C	A	C
Patients (n)	200	200	241	242	30	89	401	399	149	151	102	98	201	200	30	30	1052	1030	112	51
Age (mean) (years)	64	63	60	62	62.5	60.6	62.4	61.8	59.6	62.1	60.6	60.2	61.3	60.1	60	58.5	60.0	59.0	60.5	63
Male (%)	76	79	73	72	67.0	78.3	76.0	73.0	85.2	78.2	76.0	78.0	74.1	77.0	80	85.0	74.0	71.9	76.0	61
Hypertension (%)	46	47	46	50	43.0	35.0	70.0	71.0	34.2	41.1	62.0	63.0	65.7	62.0	—	—	48.7	47.5	56.5	61
Diabetes (%)	17	19	23	22	20.0	9.0	19.0	16.0	15.4	19.9	14.0	13.0	17.4	12.5	17	20.0	17.5	15.7	20.5	15
Previous MI (%)	10	12	17	21	7.0	6.3	10.0	11.0	14.1	7.3	—	—	—	—	—	—	14.5	12.9	12.5	14
Previous TVR (%)	6	9	14	14	10.0	9.0	4.0	2.0	28.1	23.3	8.0	13.0	11.5	10.5	—	—	14.2	12.0	4.5	8.0
Smoking (%)	39	41	41	41.0	52.0	43.3	42.0	41.0	45.0	39.7	61.0	47.0	42.8	43.5	57	52.0	42.8	43.5	21.0	31
Dyslipidemia (%)	40	39	—	—	28.0	28.0	42.0	44.0	39.6	37.1	65.0	62.0	45.8	40.5	—	—	39.2	36.6	53.5	43
Multivessel disease (%)	54	57	57	62.0	—	—	—	—	—	—	66.0	57.0	62.2	58.0	47	45.0	49.1	48.4	55.5	65
Aspirin	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Unfractionated heparin	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Clopidogrel	+	+	0	0	+	+	+	+	0	0	0	0	0	0	+	+	0	0	0	0
Ticlopidine	+	+	+	+	0	0	0	0	+	+	+	+	+	+	0	0	+	+	0	0

A, the abciximab group; C, the control group; MI, myocardial infarction.